NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
University of Michigan Rogel Cancer Center
EMD Serono
TerSera Therapeutics LLC
ASLAN Pharmaceuticals
Johannes Gutenberg University Mainz
AstraZeneca
Gyeongsang National University Hospital